L’Oreal’s Anti-Wrinkle RevitaLift Products Are Unlawfully Marketed Drugs – Class Action Complaint

The proposed class action against L’Oreal in California’s Central District is a reminder that anti-aging skin care can be a target for legal challenges, and the plaintiffs’ bar isn’t tired of bringing them.

Drugs question mark

[L'Oreal USA Inc.] is marketing unapproved drugs in defiance of federal and California food and drug law, which in turns puts it in violation of California’s Unfair Competition Law, according to a proposed class action in California’s Central District.

More from Legal

More from Policy & Regulation